Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Receivables for 6 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 1025.0% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 1025.0% increase, with the full-year FY2024 number at $2.1 million, down 14.01% from a year prior.
  • Receivables was $2.1 million for Q3 2025 at Caribou Biosciences, up from $2.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $7.6 million in Q2 2021 to a low of $184000.0 in Q3 2024.
  • A 5-year average of $2.6 million and a median of $2.2 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 93.41% in 2024, then surged 1025.0% in 2025.
  • Caribou Biosciences' Receivables stood at $1.7 million in 2021, then soared by 41.51% to $2.4 million in 2022, then rose by 0.7% to $2.4 million in 2023, then decreased by 14.01% to $2.1 million in 2024, then fell by 1.1% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Receivables are $2.1 million (Q3 2025), $2.0 million (Q2 2025), and $1.9 million (Q1 2025).